Swiss National Bank Apellis Pharmaceuticals, Inc. Transaction History

Swiss National Bank

  • $167 Billion
  • Q3 2025

A detailed history of Swiss National Bank transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Swiss National Bank holds 146,200 shares of APLS stock, worth $2.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
146,200
Previous 132,600 10.26%
Holding current value
$2.97 Million
Previous $2.9 Million 14.11%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025
BUY
$17.42 - $28.65 $236,912 - $389,640
13,600 Added 10.26%
146,200 $3.31 Million
Q1 2025

May 12, 2025
SELL
$21.87 - $34.63 $242,757 - $384,393
-11,100 Reduced 7.72%
132,600 $2.9 Million
Q4 2024

Feb 10, 2025
SELL
$26.18 - $35.42 $272,272 - $368,368
-10,400 Reduced 6.75%
143,700 $4.59 Million
Q3 2024

Nov 07, 2024
SELL
$28.84 - $41.15 $17,304 - $24,690
-600 Reduced 0.39%
154,100 $4.44 Million
Q2 2024

Aug 08, 2024
BUY
$38.07 - $59.71 $548,208 - $859,824
14,400 Added 10.26%
154,700 $5.93 Million
Q1 2024

May 07, 2024
SELL
$55.39 - $72.47 $1.22 Million - $1.6 Million
-22,100 Reduced 13.61%
140,300 $8.25 Million
Q4 2023

Feb 06, 2024
SELL
$37.14 - $64.82 $623,952 - $1.09 Million
-16,800 Reduced 9.38%
162,400 $9.72 Million
Q3 2023

Nov 08, 2023
BUY
$23.65 - $89.22 $82,775 - $312,270
3,500 Added 1.99%
179,200 $6.82 Million
Q2 2023

Aug 09, 2023
SELL
$76.68 - $93.31 $1.17 Million - $1.43 Million
-15,300 Reduced 8.01%
175,700 $16 Million
Q1 2023

May 10, 2023
SELL
$46.59 - $66.96 $987,708 - $1.42 Million
-21,200 Reduced 9.99%
191,000 $12.6 Million
Q4 2022

Feb 08, 2023
BUY
$43.24 - $61.04 $436,724 - $616,504
10,100 Added 5.0%
212,200 $11 Million
Q3 2022

Nov 09, 2022
BUY
$44.76 - $69.66 $801,204 - $1.25 Million
17,900 Added 9.72%
202,100 $13.8 Million
Q2 2022

Aug 09, 2022
BUY
$35.07 - $59.21 $108,717 - $183,551
3,100 Added 1.71%
184,200 $8.33 Million
Q1 2022

May 09, 2022
BUY
$35.46 - $54.12 $432,612 - $660,264
12,200 Added 7.22%
181,100 $9.2 Million
Q4 2021

Feb 08, 2022
BUY
$30.74 - $49.16 $1.09 Million - $1.75 Million
35,500 Added 26.61%
168,900 $7.99 Million
Q3 2021

Nov 08, 2021
BUY
$31.4 - $69.84 $15,700 - $34,920
500 Added 0.38%
133,400 $4.4 Million
Q2 2021

Aug 06, 2021
BUY
$40.9 - $64.9 $126,790 - $201,190
3,100 Added 2.39%
132,900 $8.4 Million
Q1 2021

May 07, 2021
BUY
$40.8 - $57.39 $65,279 - $91,824
1,600 Added 1.25%
129,800 $5.57 Million
Q4 2020

Feb 05, 2021
SELL
$30.79 - $57.2 $267,873 - $497,640
-8,700 Reduced 6.36%
128,200 $7.33 Million
Q3 2020

Nov 09, 2020
BUY
$25.89 - $33.65 $59,547 - $77,395
2,300 Added 1.71%
136,900 $4.13 Million
Q2 2020

Aug 05, 2020
BUY
$24.8 - $38.49 $513,360 - $796,743
20,700 Added 18.17%
134,600 $4.4 Million
Q1 2020

May 08, 2020
BUY
$17.91 - $44.33 $512,226 - $1.27 Million
28,600 Added 33.53%
113,900 $3.05 Million
Q4 2019

Feb 06, 2020
BUY
$22.1 - $30.8 $48,620 - $67,760
2,200 Added 2.65%
85,300 $2.61 Million
Q3 2019

Nov 12, 2019
BUY
$24.09 - $32.18 $48,180 - $64,360
2,000 Added 2.47%
83,100 $2 Million
Q2 2019

Aug 02, 2019
BUY
$18.0 - $25.34 $30,600 - $43,078
1,700 Added 2.14%
81,100 $2.06 Million
Q1 2019

May 10, 2019
BUY
$12.81 - $19.82 $204,960 - $317,120
16,000 Added 25.24%
79,400 $1.55 Million
Q3 2018

Nov 08, 2018
BUY
$16.57 - $21.03 $565,037 - $717,123
34,100 Added 116.38%
63,400 $1.13 Million
Q2 2018

Aug 09, 2018
BUY
$19.63 - $30.0 $575,159 - $879,000
29,300 New
29,300 $645,000

Others Institutions Holding APLS

# of Institutions
329
Shares Held
124M
Call Options Held
4.12M
Put Options Held
756K
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.23B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email